Endocrine Abstracts

My talk will focus on the best use of the most effective medications for people with osteoporosis, and how we can be more sophisticated in our use of the many drugs now available for this common, disabling, and expensive disease. Unusually in endocrinology, bone is an area where there are multiple new therapeutics, both for rare disorders and for common diseases. For osteoporosis, this growth is going to continue, with the recent FDA decision to allow bone density to be used as an end point in trials for osteoporosis. Even just considering medications already available, the default of ‘just start a generic oral antiresorptive’ is over – as is magical thinking about calcium and vitamin D! This talk will highlight data from randomised controlled trials, head-to-head comparisons, and meta-analyses; and help the audience as specialists in this area not only to model best practice individually but also to educate our colleagues, both in primary care and in hospital management about the best way we can help our ageing population to age well.